Prostate cancer: Thalidomide for prostate cancer: Is there progress?

Nature Reviews Urology

Volumn 6, Issue 5, 2009, Pages 248-250

  Efstathiou, Eleni ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; GONADORELIN;

DRUG EFFICACY; DRUG TARGETING; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR MICROENVIRONMENT; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENTIATION; HUMAN; MALE; NOTE; PATHOLOGY; PROSTATE TUMOR;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; THALIDOMIDE;

EID: 77449124448     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.68     Document Type: Short Survey

References (7)

1. Figg, w. D. et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J. Urol. 181, 1104-1113 (2009).
2. Kumar, s.&Anderson, K. C. Drug insight: thalidomide as a treatment for multiple myeloma. Nat. Clin. Pract. Oncol. 2, 262-270 (2005).
3. Figg, w. D. et al. A randomized phase ii trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7, 1888-1893 (2001).
4. Dahut, w. L. et al. Randomized phase ii trial of docetaxel plus thalidomide in androgenindependent prostate cancer. J. Clin. Oncol. 22, 2532-2539 (2004).
5. efstathiou, e. et al. initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin. Cancer Res. 13, 1224-1231 (2007).
6. Garcia, J. A. et al. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin. Cancer Res. 14, 3052-3059 (2008).
7. Mao, s. et al. employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67, 1677-1685 (2007).